Table 3.
Baseline/6-month follow-up data.
| Data | Baseline | Follow-up | P valuea | |
| Patients on whom data were collected, n | 135 | 131 |
|
|
| HCVb testing, n | 135 | 131 |
|
|
|
|
HCV antibody test, n/N (%) | 128/135 (94.8) | 128/131 (97.7) | .25 |
|
|
HCV antibody positive, n/N (%) | 100/128 (78.1) | 99/128 (77.3) | >.99 |
| Among patients with HCV antibody positivity, n/N (%) |
|
|
|
|
|
|
HCV antigen test | 38/100 (38.0) | 65/99 (65.7) | <.001 |
|
|
HCV antigen positive | 22/38 (57.9) | 37/65 (56.9) |
|
|
|
HCV RNA test | 57/100 (57.0) | 68/99 (68.7) | .002 |
|
|
HCV RNA positive | 35/57 (61.4) | 37/68 (54.4) | .63 |
| Management of patients with HCV antibody positivity |
|
|
|
|
|
|
FibroScanned, n/N (%) | 17/101 (16.8) | 52/100 (52.0) | <.001 |
|
|
FibroScan score (kPa)—lifetime, median (IQR) | 6.4 (5.6-8.4) | 7.4 (5.5-10.9) |
|
|
|
Referral to hepatology or infectious diseases, n/N (%) | 70/101 (69.3) | 84/100 (84.0) | <.001 |
|
|
Attended hepatology or infectious diseases services, n/N (%) | 51/101 (50.5) | 61/100 (61.0) | .002 |
| Treatment of patients with HCV antibody positivity, n/N (%) |
|
|
|
|
|
|
HCV treatment initiated | 20/101 (19.8) | 30/100 (30.0) | .004 |
|
|
HCV treatment completed | 14/101 (13.9) | 21/100 (21.0) | .16 |
|
|
SVRc attained | 14/101 (13.9) | 19/100 (19.0) | .32 |
aP values represent significance levels of the McNemar test.
bHCV: hepatitis C virus.
cSVR: sustained virologic response.